Author Archives: Bruno Quinney

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

DDW Highlights: 17 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research on the brain proved a popular theme, unlocking insights into Alzheimer’s, dementia… Read More

#Podcasts

#Autoimmune disease #Biotech #Immunotherapy

Commit Biologics appoints CEO, advances therapeutics pipeline 

Biotechnology company Commit Biologics has appointed Thomas Montgomery Andresen as CEO as it aims to take its complement-powered immune engagers into clinic.  Commit described Andresen as “a serial biotech entrepreneur”, with over 20 years of experience building high-value biotech ventures at the intersection of therapeutic innovation and bioengineering.  … Read More

#News

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

This week in Drug Discovery (9 – 13 March) 

News round-up for 9 – 13 March February by Bruno Quinney, Content Team at DDW.  This week, research on the brain has proved a popular theme, unlocking insights into Alzheimer’s, dementia and cancer. Elsewhere, a genetic target could provide new routes to breast cancer treatment.  The top stories: … Read More

#News

Conference speaker
#Biotech #ELRIG #Screening

ELRIG announces keynote speakers for Gothenburg conference 

ELRIG has announced the keynote speakers for its ‘Advances in Cell-Based Screening 2026’ conference.  Professor Hazel Screen (Queen Mary University of London) and Dr Dave Powell (Relation Therapeutics) will deliver the keynote presentations during the free-to-attend event, which takes place on 6 and 7 May at AstraZeneca in Gothenburg,… Read More

#News

Cancer research in laboratory
#Antibody drug conjugate (ADC) #Biotech #Breast cancer

VALANX raises €3m to advance breast cancer ADC programme 

Biotech company VALANX Biotech has raised €3 million to advance its lead antibody-drug conjugate (ADC) programme to treat metastatic triple-negative breast cancer.  The company will use the financing for the pre-clinical development of VLX-ADC-001, a LIV-1-targeting ADC for metastatic triple-negative breast cancer (mTNBC), with candidate selection planned for June 2026.  ADCs are a… Read More

#Business & Investment #News

#Cancer research #Nuclear medicine #Radiopharmaceuticals #UK

UK project to develop ‘cutting edge’ radiopharmaceuticals 

A £19 million ($25 million) UK programme is set to power the recycling of nuclear materials to develop cutting edge treatments for cancer.  Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create… Read More

#Cancer Research #News

Human eye
#Clinical trial #Ophthalmology #Preclinical development #Revvity

Preclinical advancements in ophthalmology drug development

Dr Jess Pesner and Caleb Proctor, Revvity, explore the use of in vivo, in vitro models, and in silico models in the quest for new treatments for diseases of the eye. Within drug and device approval paths, regulated steps protect the well-being of the public and offer hope for those who may be battling a disease or a life event that may currently not… Read More

#Exclusive Content

#Clinical trial #Infertility #Monoclonal antibodies

A new approach to treating infertility

DDW Editor Reece Armstrong speaks to Elke Bestel, Chief Medical Officer at Igyxos, about the treatment space for infertility and how the company’s monoclonal antibody IGX12 could represent a differentiated approach.   RA: Why have treatments for infertility remained limited?  EB: Developing treatments for infertility has been and is still complex. First of all, infertility can result from hormonal, anatomical, metabolic,… Read More

#Exclusive Content

#Breast cancer #Genetics #Institute of Cancer Research #King's College London

Research uncovers genetic target for aggressive breast cancer 

Researchers have identified a gene which could provide new routes for breast cancer treatment.  Scientists from the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research (ICR), London and the Breast Cancer Now Research Unit at King’s College London, have uncovered a new weakness in triple… Read More

#Cancer Research #News

#Biotech #India #Peptides

Commercial peptide facility to support biotech programmes 

An expanded commercial peptide facility in India will open to support emerging biotech programmes.  CDMO Neuland Laboratories will open its new commercial peptide facility in the summer of 2026 at its 17-acre Bonthapally manufacturing campus, with further capacity expansions planned as client demand increases.   The first of four… Read More

#News

Modern medical science laboratory
#Cancer research #Oncology #Paediatrics

C-Further announces oncology therapeutic programmes 

C-Further has unveiled its first early-stage therapeutic programmes dedicated to paediatric oncology indications.  The international consortium is set to advance CF-012 for the treatment of Ewing sarcoma, in collaboration with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham, and has also partnered with MiNK Therapeutics to… Read More

#Cancer Research #News

#Biomarkers #Clinical trial #Genomics

Driving precision drug discovery with genomics

Dharminder Singh Chahal, Chief Executive Officer at SkylineDx, discusses the real-world applications of how SkylineDx bridges biomarker insights to therapeutic development. Real-world applications     As the healthcare landscape continues to evolve toward personalised, data-driven care, clinically validated diagnostic tests with real-world data integration are redefining how diseases are diagnosed, stratified, and treated. Recent advances in genomics have significantly reshaped the landscape of drug discovery and… Read More

#Exclusive Content

pulmonary arterial hypertension
#FDA #Hypertension #nda

FDA accepts NDA for hypertension treatment option 

The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for hypertension drug lorundrostat.  Biopharmaceutical company Mineralys Therapeutics announced the NDA for lorundrostat was accepted for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action… Read More

#News #Regulatory

Cancer patient receives chemotherapy via IV
#Cancer research #Clinical trial #kainova #Solid tumours

Positive results announced for metastatic tumour treatment 

A new anti-tumour treatment for metastatic solid tumours has achieved encouraging results in a Phase I clinical trial.  DT-9081, developed by biopharmaceutical company Kainova Therapeutics, is a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumours.  According to Kainova, the… Read More

#Cancer Research #News

#Biomarkers #Clinical trial #Lundbeck #Neuroscience #Research and development

Are biomarkers the key to derisking neuroscience R&D?

Jesper Frank Bastlund, Senior Director in Biological and Translational Research, and Enchi Liu, Vice President, Head of Experimental Medicine at Lundbeck, examine how biomarkers can help advance the field of neuroscience.  Navigating the challenges of CNS Drug development   Neuroscience research and development has historically been one of the most challenging areas in… Read More

#Exclusive Content

Bacteria
#Centauri Therapeutics #FDA #Gram-negative bacteria

Gram-negative bacterial infection treatment gets QIDP status 

The US Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to a novel treatment of Gram-negative bacterial infections.  CTX-187, developed by immunotherapy company Centauri Therapeutics, is a novel immunotherapeutic approach to treat Gram-negative bacterial infections. It is hoped the therapeutic, currently in preclinical development ahead of… Read More

#News #Regulatory